January Therapeutics Announcement New Head Of Early Research and Development prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
January Therapeutics Announces Appointment of Dr. Daniel C. Maneval, PhD as Chief Scientific Officer
Share Article
As Chief Scientific Officer Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs SAN DIEGO (PRWEB) April 27, 2021 January Therapeutics today announced the appointment of Daniel C. Maneval, PhD, as Chief Scientific Officer. Dr. Maneval will lead key aspects of the Scientific Team for January’s oncology programs including the JNTX-101 program (pro-drug albumin-encapsulated version of gemcitabine for cancer treatment) and JNTX-104 (albumin-encapsulated 8-chloro-adenosine for AML), and other undisclosed targets.
Dr. Maneval is the former Vice President of Research & Nonclinical Development at Halozyme Therapeutics where he led the expansion of Halozyme’s core technology platforms. In that role he was also an integral part of the team working with strategic